TrovaGene, Inc. (TROV) Shares Down 0.6%
Shares of TrovaGene, Inc. (NASDAQ:TROV) dropped 0.6% during trading on Friday . The stock traded as low as $0.78 and last traded at $0.80. Approximately 264,539 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 627,998 shares. The stock had previously closed at $0.81.
TROV has been the topic of several research analyst reports. Maxim Group set a $4.00 price target on shares of TrovaGene and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Cantor Fitzgerald reiterated an “overweight” rating on shares of TrovaGene in a research note on Tuesday, August 8th.
The company’s market cap is $30.00 million. The company has a 50 day moving average of $0.74 and a 200 day moving average of $0.87.
Several hedge funds and other institutional investors have recently made changes to their positions in TROV. Two Sigma Securities LLC grew its position in shares of TrovaGene by 262.4% in the first quarter. Two Sigma Securities LLC now owns 120,516 shares of the medical research company’s stock valued at $139,000 after purchasing an additional 87,264 shares during the period. LMR Partners LLP acquired a new stake in shares of TrovaGene in the second quarter valued at about $151,000. Susquehanna International Group LLP grew its position in shares of TrovaGene by 2,781.0% in the second quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock valued at $174,000 after purchasing an additional 133,240 shares during the period. KCG Holdings Inc. grew its position in shares of TrovaGene by 560.1% in the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock valued at $242,000 after purchasing an additional 178,440 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of TrovaGene by 1,079.5% in the second quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock valued at $351,000 after purchasing an additional 254,601 shares during the period. Institutional investors and hedge funds own 8.94% of the company’s stock.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Stock Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related stocks with our FREE daily email newsletter.